Archive for: English

Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025

, , ,
Today, January 17, 2025, an Extraordinary General Meeting was held in Diagonal Bio AB. A summary of the adopted resolutions follows below. Resolution on reduction of the share capital for allocation to non-restricted equity The general…

Diagonal Bio expands its testing panel for horses with EHV-5 detection

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces the expansion of its equine diagnostic testing panel to include the detection of Equine Herpesvirus type 5 (EHV-5), following the recommendation of Daniel Redén –…

Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into a partnership with Diagonal Bio and will act as a marketing partner for the Company to enhance…

Renowned horse race jockey and trainer conducts pilot test of LAMPlify®

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that one of Sweden’s most accomplished horse race trainers, Madeleine Smith, has initiated a six-month pilot test of LAMPlify®.  The pilot test will focus on enhancing…

Nomination Committee appointed for Diagonal Bio

, ,
Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.According to the instruction for the Nomination Committee adopted by the AGM in 2024, the Nomination…

Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Kolgjini Stables (Stall Kolgjini), founded by renowned harness racer Lutfi Kolgjini, to conduct a three-month pilot test. Kolgjini Stables is a Swedish stable…

Diagonal Bio announces that it is exploring financing options

, , , ,
Diagonal Bio AB ("Diagonal Bio" or "the Company") today announces that the Board of Directors of the Company has engaged financial and legal advisors and decided to explore potential financing alternatives to secure the Company’s ongoing…

Diagonal announces first pilot test at a stud with LAMPlify®

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Gocksta Stud (Gocksta Stuteri), led by Anne-Sophie Thiam, to conduct a three-month pilot study, which begins immediately. This pilot test will evaluate LAMPlify’s…

Diagonal Bio AB Third Quarter Report (Q3 2024)

, , , , , , ,
“One of the most exciting developments is our effort into a new application of our technology LAMPlify®—this time in the domain of swine diseases.”Summary of Q3 report 20242024-07-01 — 2024-09-30 (July — September…

Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify®, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot,…